ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 151 filers reported holding ARGENX SE in Q4 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,974,029 | -9.3% | 32,135 | -31.3% | 0.01% | 0.0% |
| Q2 2023 | $18,721,932 | -25.5% | 46,806 | -26.5% | 0.01% | -45.5% |
| Q4 2022 | $25,123,765 | +56999.5% | 63,719 | +40745.5% | 0.01% | – |
| Q1 2021 | $44,000 | +76.0% | 156 | +75.3% | 0.00% | – |
| Q4 2020 | $25,000 | +25.0% | 89 | +17.1% | 0.00% | – |
| Q3 2020 | $20,000 | -85.5% | 76 | -91.2% | 0.00% | – |
| Q4 2019 | $138,000 | +34.0% | 862 | -5.0% | 0.00% | – |
| Q3 2019 | $103,000 | -98.8% | 907 | -98.4% | 0.00% | -100.0% |
| Q2 2019 | $8,274,000 | +84.5% | 58,441 | +62.7% | 0.01% | +75.0% |
| Q1 2019 | $4,485,000 | +1850.0% | 35,921 | +1401.1% | 0.00% | – |
| Q4 2018 | $230,000 | +14.4% | 2,393 | -9.8% | 0.00% | – |
| Q3 2018 | $201,000 | -8.6% | 2,653 | 0.0% | 0.00% | – |
| Q2 2018 | $220,000 | +3.3% | 2,653 | 0.0% | 0.00% | – |
| Q1 2018 | $213,000 | +12.7% | 2,653 | -11.6% | 0.00% | – |
| Q4 2017 | $189,000 | – | 3,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SAL Trading, LLC | 36,100 | $17,747,843 | 24.88% |
| Artia Global Partners LP | 49,238 | $24,206,878 | 10.06% |
| Paradigm Biocapital Advisors LP | 261,443 | $128,533,222 | 8.72% |
| Darwin Global Management, Ltd. | 45,615 | $22,425,702 | 7.89% |
| Avoro Capital Advisors LLC | 1,000,000 | $491,630,000 | 7.67% |
| Bellevue Group AG | 911,530 | $448,135,494 | 7.22% |
| Eagle Health Investments LP | 64,400 | $31,660,972 | 6.98% |
| DCF Advisers, LLC | 22,000 | $10,815,860 | 5.89% |
| SAL Trading, LLC | 8,149 | $4,006,293 | 5.62% |
| RTW INVESTMENTS, LP | 507,195 | $249,352,278 | 5.26% |